Novartis AG Common Stock (NVS)

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and

UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates.

Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.

These companies have successfully navigated similar obstacles before.

These stocks look like they can weather almost any storm.

Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

Truist, however, kept a ‘Buy’ rating on the shares.

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

The company is focused on treatments for forms of muscular dystrophy.